GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.
GSK in breach for misleading prescribing information on Omjjara, industry body says
British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and prescription information for its Omjjara drug, an industry self-regulatory body said on Tuesday.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
US FDA approves GSK's urinary tract infection drug
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.
GSK studying if best-selling shingles vaccine lowers dementia risk
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
GSK says European regulator reviewing expanded use of asthma drug Nucala
GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
